Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Autor: Martin Dreyling, Michael Dickinson, Joaquin Martinez Lopez, Arne Kolstad, Jason P Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, Phoebe Joy Ho, Jose A. Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J M Ferreri, Takanori Teshima, Piers E.M. Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O'Donovan, Roberto Ramos, Aisha Masood, Catherine Thieblemont, Nathan H. Fowler, Stephen J. Schuster

Publikováno v: Blood. 140:1459-1463

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::548dc2e074aaccf8ffbf7c72c3a598cb
https://doi.org/10.1182/blood-2022-158024

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Autor: Piers E.M. Patten, Julio C. Chavez, P. Joy Ho, Monalisa Ghosh, Jason Butler, Bastian von Tresckow, Andreas L. Petzer, Arne Kolstad, Alessandra Forcina, Catherine Thieblemont, José A. Pérez-Simón, Sarah J. Nagle, Pier Luigi Zinzani, Lida Bubuteishvili Pacaud, Joseph McGuirk, Aiesha Zia, Charalambos Andreadis, Michael Dickinson, Stephen J. Schuster, Marie José Kersten, Andrés J.M. Ferreri, Hideo Harigae, Loretta J. Nastoupil, Peter A. Riedell, Martin Dreyling, Fritz Offner, Ram Malladi, Andreas Viardot, Takanori Teshima, Koji Kato, Leslie Popplewell, Emmanuel Bachy, Joaquin Martinez-Lopez, Nathan Fowler

Publikováno v: Blood. 136:1-3

Background: Follicular lymphoma (FL) remains an incurable disease for most patients (pts), characterized by a relapsing and remitting pattern. For pts with relapsed/refractory (r/r) FL, treatment outcomes typically worsen with each subsequent line of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::09dbaa35228b0747d49d193b26644f58
https://doi.org/10.1182/blood-2020-138983

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Autor: Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez-Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont

Publikováno v: Nature medicine. Nature Publishing Group
Fowler, N H, Dickinson, M, Dreyling, M, Martinez-Lopez, J, Kolstad, A, Butler, J, Ghosh, M, Popplewell, L, Chavez, J C, Bachy, E, Kato, K, Harigae, H, Kersten, M J, Andreadis, C, Riedell, P A, Ho, P J, Pérez-Simón, J A, Chen, A I, Nastoupil, L J, von Tresckow, B, Ferreri, A J M, Teshima, T, Patten, P E M, McGuirk, J P, Petzer, A L, Offner, F, Viardot, A, Zinzani, P L, Malladi, R, Zia, A, Awasthi, R, Masood, A, Anak, O, Schuster, S J & Thieblemont, C 2021, ' Tisagenlecleucel in adult relapsed or refractory follicular lymphoma : the phase 2 ELARA trial ', Nature Medicine . https://doi.org/10.1038/s41591-021-01622-0

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r fol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20181be423bbabd176ce4e8d2b786215
http://hdl.handle.net/11585/866829

Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)

Autor: Stephen J. Schuster, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter Riedell, Aiesha Zia, Mony Chenda Morisse, Nathan Hale Fowler, Catherine Thieblemont

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S245

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba76b6ce15cf48eab4d0b901f5623de0
https://doi.org/10.1016/s2152-2650(21)01539-1

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias

Autor: Vicky Huang, Giovan Battista Ruffo, John B. Porter, Raquel Merino Herranz, Ai-Sim Goh, Ali Taher, Raffaella Origa, Antonis Kattamis, Alexandra Kouraklis, Silverio Perrotta, Aiesha Zia

Publikováno v: Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-12 (2018)

Background Adherence to long-term chelation therapy in transfusion-dependent patients is critical to prevent iron overload-related complications. Once-daily deferasirox dispersible tablets (DT) have proven long-term efficacy and safety in patients �

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63bfc06e5e0fefe85f7747e865e421af
http://europepmc.org/articles/PMC6245526